返回 A A A Font Size Receive E-mail Alerts Press Releases

WALTZ™ Gains Regulatory Approval in Brazil

[2017-11-24] 

 Brasilia, Brazil – On October 30, WALTZ™ CoCr Coronary Stent System ("WALTZ™"), in-house developed by Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®"), received approval from Brazil's National Health Surveillance Agency (in Portuguese, Agência Nacional de Vigilância Sanitária - ANVISA). The product had received CE mark and gained regulatory approvals in Argentina, Peru, the Philippines, Indonesia, and etc.
 
WALTZ™ is indicated for the treatment of coronary artery stenosis or occlusion. It has L605 Cobalt-Chromium alloy stent architecture with three different stent designs. As the third-generation bare metal stent of MicroPort®, WALTZ™ has strong radial strength and excellent flexibility, crossability, trackability, and pushability to achieve the best surgical outcome.
 
Aside from WALTZ™, MicroPort®’s Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®"), Firefighter™ PTCA Balloon Dilatation Catheter ("Firefighter™ PTCA"), and other coronary interventional products also obtained regulatory approval in Brazil. As WALTZ™ is permitted to be officially launched in the Brazil market, MicroPort® will further diversify its cardiovascular product line with accelerated product upgrading. With its outstanding performance, WALTZ™ is expected to help MicroPort® further consolidate and expand its coronary products' market share in Brazil and other the overseas markets.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 

[Prev]:MicroPort® NeuroTech Attends 17th OCIN
[Next]:MicroPort® Hosts Firehawk® SAFE Study Protocol Symposium